Akston's first Ambifect(R) immuno-enhancing protein enters clinical trial at Purdue University, with Dutch Shepherd Rocco as the first patient -- Akston has launched a clinical study at Purdue ...

Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer Safety and Tolerability of ...

Solna, Sweden, November 7, 2025 - Vivesto AB, an oncology-focused development company, today announced positive interim results obtained in Vivesto's open label, clinical pilot study with Paccal Vet i ...